AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaTechnology, Industry, AgricultureHumanitiesInformation ScienceNamed GroupsHealth CareGeographicals
AutomobilesHematopoietic Stem Cell TransplantationIsocyanatesTransplantation, HomologousGasolineTransplantation, AutologousDermatitis, OccupationalPaintPolyurethanesCyanatesGraft vs Host DiseaseAir Pollutants, OccupationalCameroonTransplantation ConditioningSyringesHematologic NeoplasmsTreatment OutcomeOccupational ExposureAutoantibodiesTime FactorsSensitivity and SpecificityEvaluation Studies as TopicMultiple MyelomaReproducibility of ResultsFollow-Up StudiesAutoantigensB-LymphocytesFlow CytometryRetrospective StudiesAlgorithmsTissue DonorsProspective StudiesGraft vs Leukemia EffectLeukemiaMyeloablative AgonistsChimerismHistocompatibilityHematologic DiseasesHistocompatibility TestingBusulfanTransplantation ChimeraMycosesWhole-Body IrradiationHepatic Veno-Occlusive DiseaseVidarabineRecurrenceCytomegalovirus InfectionsMolecular Sequence DataAspergillosisCord Blood Stem Cell TransplantationGraft vs Tumor EffectAntilymphocyte SerumSurvival AnalysisSiblingsPeripheral Blood Stem Cell TransplantationDonor SelectionSevere Combined ImmunodeficiencyLeukemia, Myeloid, AcuteBone Marrow TransplantationImmunocompromised HostLymphoproliferative DisordersAcute DiseaseStem Cell TransplantationMyelodysplastic SyndromesEuropeLymphohistiocytosis, HemophagocyticBronchiolitis ObliteransTransplantationSurvival RateImmunosuppressive AgentsHLA AntigensOpportunistic InfectionsPrecursor Cell Lymphoblastic Leukemia-LymphomaGraft SurvivalDisease-Free SurvivalAnemia, AplasticRisk FactorsRemission InductionCytomegalovirusCystitisEnzyme Replacement TherapyThermometryTransplantation ImmunologyLymphocyte DepletionT-LymphocytesStomatitisCombined Modality TherapyImmunosuppressionSurvivorsMediterranean RegionNeoplasmsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveCyclophosphamideRoseolovirus InfectionsReceptors, KIRGanciclovirPlatelet TransfusionAntifungal AgentsCohort StudiesAdjustment Disorders
Hematopoietic stem cellTransplantationAutologousAllogeneic-HSCT recipientsLymphomaAntigen receptorAcute lymphoblRelapseUnrelated-donorRefractoryHaploidenticalAutoimmune diseasesTherapiesBone marrowPatientsRecipientsCellsProgressionTransplantChimeric antigenParticipantsCell therapyToxicityImmuneOutcomesDonorsTherapyTherapeuticHospitalOutcomeDisordersRapidlyCord bloodInfusion
Hematopoietic stem cell4
  • Patients undergoing autologous hematopoietic stem cell transplant (auto-HSCT) for lymphoma or myeloma have an increased risk of acute myeloid. (mdedge.com)
  • Hematopoietic stem cell transplant (HSCT) recipients and CAR T-cell therapy recipients are recommended to consult with their physician regarding COVID-19 vaccine spacing. (alberta.ca)
  • The drug candidate is also under development for bone marrow conditioning before a hematopoietic stem cell transplant (HSCT), in relapsed/refractory elderly AML patients. (pharmaceutical-technology.com)
  • Immunocompromised patients who have received a hematopoietic stem cell transplant (HSCT) have an incidence of active tuberculosis infection that is 10 to 40 times higher than the general population. (contagionlive.com)
Transplantation17
Autologous5
  • Cells for HSCT may be obtained from the patient himself or herself (autologous transplant) or from another person, such as a sibling or unrelated donor (allogeneic transplant) or an identical twin (syngeneic transplant). (medscape.com)
  • In the analysis, the investigators included 200 patients made up of 63 allogeneic-HSCT recipients, 74 autologous-HSCT recipients, and 63 HSCT donors. (contagionlive.com)
  • Case presentation Here, we report a case of a refractory MCL in a patient who had relapsed after conventional chemotherapy and autologous CAR T cell therapy. (bmj.com)
  • Conclusions This case suggests that haplo-CAR T cell therapy can be effective in controlling lymphoma that failed to respond to autologous CAR T cell therapy and overcome limitation of autologous CAR T cells, thus may be one possible regimen before the era of off-the-shelf "universal" CAR T cell therapy. (bmj.com)
  • Autologous HSCT is the most commonly used technique, and an expanding body of evidence supports its utility in treating a broad range of autoimmune conditions, such as relapsing remitting MS, systemic sclerosis, CIDP, Stiff Person Syndrome, Systemic Sclerosis, Myasthenia Gravis, and Crohn's disease. (hsctindia.com)
Allogeneic-HSCT recipients1
  • In the section on aspergillosis, the revised recommendations include the use of a room with high-efficiency particulate air filters rather than laminar airflow as the protective environment for allogeneic HSCT recipients and the use of high-efficiency respiratory-protection devices (e.g. (cdc.gov)
Lymphoma9
  • Attendees at the 2021 Pan Pacific Lymphoma Conference heard from one of the leading Chinese investigators, Peihua (Peggy) Lu, MD , of Lu Daopei Hospital, who described the progress being made in CAR T-cell therapy development in China, including two recent promising endeavors: the phase I study on synthetic T-cell antigen receptor (STAR-T) and FasT CAR T-cell therapy program. (ascopost.com)
  • The one CAR T-cell product approved so far by China's National Medical Products Administration-axicabtagene ciloleucel (for lymphoma)-costs around $185,000 (in U.S. dollars) vs $373,000 in the United States. (ascopost.com)
  • CAR-T cells, which incorporate an antibody-derived extracellular receptor and T cell derived intracellular signaling domains, have shown convincing outcomes in certain types of leukemia and lymphoma, including commercial licensure of CD19 CAR-Ts for the treatment of relapsed/ refractory large B cell lymphoma and acute lymphoblastic leukemia. (bdbiosciences.com)
  • We retrospectively analyzed patients who received auto-SCT for treatment of relapsed or refractory non-Hodgkins lymphoma or Hodgkins disease between the years of 1996 and 2007. (elsevierpure.com)
  • CAR-T cell therapy has shown to be a viable treatment for mantle cell lymphoma after being studied at the University of Texas MD Anderson Cancer Center. (patientworthy.com)
  • Although chimeric antigen receptor (CAR) T-cell therapy has been a life-saving treatment for some patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and other hematologic malignancies, additional therapies may be able to perform equally well in select patients, according to Andrew D. Zelenetz, MD, PhD, Medical Director, Quality Informatics, Memorial Sloan Kettering Cancer Center, New York City. (theoncologynurse.com)
  • So far, the FDA approved 3 CAR T-cell therapies, including tisagenlecleucel (Kymriah) for relapsed or refractory B-cell precursor acute lymphoblastic leukemia and for relapsed or refractory DLBCL, axicabtagene ciloleucel (Yescarta) for relapsed or refractory DLBCL, and most recently, brexucabtagene autoleucel (Tecartus) for relapsed or refractory mantle-cell lymphoma. (theoncologynurse.com)
  • A fourth CAR T-cell therapy, lisocabtagene maraleucel, has recently been submitted for FDA approval for relapsed or refractory large B-cell lymphoma. (theoncologynurse.com)
  • While HSCT has long been employed to treat specific cancers, such as leukaemia and lymphoma, recent studies have explored its effectiveness in treating autoimmune diseases, including MS. In fact, MS has been shown to respond extremely well to HSCT, with patients experiencing substantial symptom improvement and long-term remission. (hsctindia.com)
Antigen receptor12
  • Conversely, at the other boundary, immune hypersensitivity with gain of immune function in MHC class II-associated sJIA-AOSD and with chimeric antigen receptor (CAR) T cell therapy also triggers MAS. (nature.com)
  • This phase I trial studies the best dose and side effects of CD19/CD22 chimeric antigen receptor (CAR) T cells when given together with chemotherapy, and to see how well they work in treating children or young adults with CD19 positive B acute lymphoblastic leukemia that has come back or does not respond to treatment. (stanford.edu)
  • SummaryChimeric antigen receptor T cells (CAR-T cells) are a novel form of cellular immunotherapy for patients with hematologic and oncologic malignancies. (deepdyve.com)
  • SummaryChimeric antigen receptor (CAR) T cells are genetically engineered cells containing fusion proteins combining an extracellular epitope-specific binding domain, a transmembrane and signaling domains of the T cell receptor. (deepdyve.com)
  • Some of the most impressive data on chimeric antigen receptor (CAR) T-cell therapy have come from studies conducted in China. (ascopost.com)
  • While chimeric antigen receptor (CAR)-T cell therapy has demonstrated positive response rates in children with relapsed and/or refractory CD19-positive acute lymphoblastic leukemia (ALL), severe toxicities can also be associated with such treatment. (curetoday.com)
  • Engineered chimeric antigen receptor (CAR) T cell therapies (CAR-T) are now commercially available to treat certain leukemias and lymphomas. (bdbiosciences.com)
  • Chimeric antigen receptor-modified T (CAR T) cells exhibit very effective function in elimination of relapsed/refractory B-cell lymphoid malignancies, we investigated their use in a patient with relapsed MCL. (bmj.com)
  • Although anti-CD19 chimeric antigen receptor (CAR) T-cell therapy shows good efficacy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), it fails to improve long-term leukemia-free survival (LFS). (biomedcentral.com)
  • There is an unmet need to develop novel therapies for refractory/relapsed MM. In the past few years, chimeric antigen receptor (CAR)-modified T cell therapy for MM has shown promising efficacy in preclinical and clinical studies. (biomedcentral.com)
  • Chimeric antigen receptor (CAR) T cell therapy has emerged as a novel immunotherapy which modifies T cells with CAR, an artificial fusion protein that incorporates an extracellular antigen recognition domain, a transmembrane domain, and an intracellular domain including costimulation and signaling components [ 4 , 5 ]. (biomedcentral.com)
  • [ 2 ] Options for second-line therapy in patients with relapsed/refractory disease include chemotherapy-free regimens with biologic targeted agents such as covalent Bruton tyrosine kinase (BTK) inhibitors, lenalidomide,venetoclax, and chimeric antigen receptor (CAR) T-cell therapy. (medscape.com)
Acute lymphobl2
  • Giving CD19/CD22-CAR T cells and chemotherapy may work better in treating children or young adults with B acute lymphoblastic leukemia. (stanford.edu)
  • CAR-T cell therapy has been showing promising in treating children with acute lymphoblastic leukemia, but it can come with significant toxicities. (curetoday.com)
Relapse8
  • Although many patients achieve complete responses to CAR T-cell therapy, some 40% relapse. (ascopost.com)
  • 3 Of this group, 75 went on to allo-HSCT, after which, relapse occurred in 10% of MRD-negative patients and 50% of MRD-positive patients. (ascopost.com)
  • The workshop will present the latest scientific and clinical advances related to relapse after HSCT and to provide a forum for the presentation of ongoing laboratory, translational, and clinical research. (astct.org)
  • Recent clinical data indicate that patients with complex karyotypes, adverse genes, and high pre-infusion minimal residual disease (MRD) by flow cytometry in the bone marrow, were at high risk of relapse after CAR T-cell therapy. (biomedcentral.com)
  • High pre-lymphodepletion lactate dehydrogenase, low pre-lymphodepletion platelet count, absence of fludarabine in lymphodepletion, persistent leukemic sequence by high throughput sequencing in bone marrow after CAR T-cell infusion, and early loss of CAR T cells have also been linked to relapse after CAR T-cell therapy. (biomedcentral.com)
  • Early loss or exhaustion of CAR T cells, selection of CD19-negative clones, downregulation of CD19 expression, lineage switch of leukemia, and tumor microenvironment are important factors contributing to relapse after CAR T-cell therapy [ 9 , 10 ]. (biomedcentral.com)
  • The combination of CAR T-cell therapy and allo-HSCT has been suggested to reduce the relapse rate of leukemia. (biomedcentral.com)
  • Patients with NMO who underwent HSCT experienced a 77% reduction in relapse rates and a 90% reduction in disability scores in a single study, with no significant negative effects. (hsctindia.com)
Unrelated-donor2
  • The National Marrow Donor Program (NMDP), founded in 1986, and the World Marrow Donor Association (WMDA), founded in 1988, were established to (1) locate and secure appropriate unrelated-donor HSCT sources for patients by promoting volunteer donation of bone marrow and peripheral blood stem cells in the community and (2) promote ethical practices of sharing stem cell sources by need, rather than by geographic location of the donor. (medscape.com)
  • 2020/2022 CMV infection and CMV-specific T-cell reconstitution in unrelated donor allo-HSCT after in vivo T-cell depletion with ATG: a comparative study of prophlylaxis with letermovir versus standard of care preemptive. (ulisboa.pt)
Refractory3
  • Lisocabtagene maraleucel is a new CD19-directed CAR T-cell therapy that was studied in the TRANSCEND trial in patients with relapsed or refractory heavily pretreated DLBCL (Abramson JS, et al. (theoncologynurse.com)
  • Studies show that all 3 CAR T-cell agents represent a new treatment for relapsed or refractory DLBCL. (theoncologynurse.com)
  • A randomized trial is needed to compare CAR T-cell therapy to ASCT before CAR T-cell replaces transplant" in patients with relapsed or refractory DLBCL. (theoncologynurse.com)
Haploidentical2
  • With her expertise in T-cell depleted transplant and haploidentical HSCT, along with her several certifications and training, Dr. Smitha is a highly sought-after specialist. (hcgoncology.com)
  • Dr. Smitha's special interest lies in T cell-depleted transplant and haploidentical HSCT. (hcgoncology.com)
Autoimmune diseases2
  • He has successfully taken research discoveries to the bedside and has been instrumental in establishing many of the clinicial HSCT procedures and current clinical trials including HSCT for severe autoimmune diseases and HIV. (edu.au)
  • Considering that there are millions of patients worldwide who suffer from autoimmune diseases, HSCT treatment must become more accessible. (hsctindia.com)
Therapies6
  • Research is currently evaluating the use of stem cell transplants (HSCT) and experimental gene therapies as avenues for treatment in limited subsets of PIDs. (wikipedia.org)
  • Certainly, one difference between CAR T-cell therapies in the United States and those in China is cost, Dr. Lu emphasized. (ascopost.com)
  • Because children with cancer interface with multiple aspects of the health care system, we hope that these guidelines will facilitate wider education across health care disciplines to ensure early signs/symptoms of toxicity are not missed and prevent medical management errors that could impact the efficacy of CAR-T cell therapies," Mahadeo said. (curetoday.com)
  • Creation of institutional Readiness Guidelines for CAR T-cell therapies and 4 categories of ATMPs and dissemination of the work with the wider European pharmacists (involvement and review by EBMT Pharmacists' committee members of different European countries: on-going). (ebmt.org)
  • Dr Burt is starting a new HSCT trial for patients with RR who have failed 1st line therapies. (mssociety.org.uk)
  • More recently, we engaged in developing several novel strategies for CAR T cell therapies of hematologic malignancies and solid tumors. (ulisboa.pt)
Bone marrow3
  • Further, the HSCT was peripheral blood in 83 patients, bone marrow in 21, and primed-bone marrow in 21 patients. (contagionlive.com)
  • Launch survey for assessment of extent of clinical pharmacists' and pharmacologists' involvement in HSCT in Europe on the basis of the 2020 published publication (Bone Marrow Transplant, 2020 Jan;55(1):62-69). (ebmt.org)
  • HSCT is a medical procedure that entails the removal of stem cells from a patient's bone marrow. (hsctindia.com)
Patients18
  • In order to better understand the LPI kinetics and its determinants and implications, we undertook sequential LPI determinations before and after conditioning until engraftment in 25 auto-HSCT patients. (karger.com)
  • In the first study, 45 of 53 patients achieved complete remission after CAR T-cell treatment and achieved measurable residual disease (MRD)-negative status, whereas 22 relapsed early. (ascopost.com)
  • The conclusion was that you really need to consider consolidation and allogeneic transplant in patients achieving complete remission from CAR T-cell therapy (especially high-risk patients), unless future randomized trials show no benefit," Dr. Lu said. (ascopost.com)
  • These guidelines are meant to be a truly comprehensive guide to ensure safe delivery of CAR-T therapy to pediatric patients," Kris Mahadeo, M.D., associate professor of Pediatrics and chief of Stem Cell Transplant and Cellular Therapy at MD Anderson, said in an interview with CURE . (curetoday.com)
  • As CAR T-cell therapy becomes more widely used - it has since expanded in to adult patients and other blood cancer types - researchers from at The University of Texas MD Anderson Cancer Center and the Pediatric Acute Lung Injury and Sepsis Investigators Network (PALISI) collaborated to provide an expert consensus on the care for children treated with CAR-T cell therapy. (curetoday.com)
  • A study conducted at the Salvador Zubirán National Institute of Health Sciences and Nutrition found that there were no cases of active tuberculosis detected in HSCT patients. (contagionlive.com)
  • For the study, the investigators conducted a retrospective analysis of clinical data from patients who underwent a HSCT between January 2010 and December 2016 at the Salvador Zubirán National Institute of Health Sciences and Nutrition. (contagionlive.com)
  • Nevertheless, which patients are likely to benefit from consolidative allo-HSCT, as well as the optimal therapeutic window, remain to be explored. (biomedcentral.com)
  • In patients having these risk factors, consolidative allo-HSCT after CAR T-cell therapy may prolong LFS. (biomedcentral.com)
  • Allo-HSCT provides optimal clinical benefit in patients with MRD-negative complete remission, typically within three months after CAR T-cell therapy. (biomedcentral.com)
  • Finally, and most importantly, we provide recommendations for the assessment and management of r/r B-ALL patients undergoing anti-CD19 CAR T-cell therapy. (biomedcentral.com)
  • Furthermore, r/r B-ALL patients may develop severe organ damage or infection after aggressive chemotherapy and, hence, be precluded from allo-HSCT. (biomedcentral.com)
  • Nonetheless, consolidative allo-HSCT is not recommended for all patients because it will increase the economic burden and bring risk of severe toxicity, such as graft-versus-host disease (GVHD). (biomedcentral.com)
  • The cumulative incidence of any IFD was 32.6% in allo-HCT, 22.2% in PHO, and 6.0% in auto-HCT patients. (viamedica.pl)
  • The risk of IFD in allo-HCT patients is much higher than in auto-HSCT and PHO patients. (viamedica.pl)
  • CAR T-cell therapy can be lifesaving for some patients, but because CAR T-cells are genetically engineered through a laborious process, the treatment is very expensive. (theoncologynurse.com)
  • For chemosensitive patients, it's not clear that CAR T-cell is superior to high-dose chemotherapy and stem-cell transplant if the patient is PET-positive after chemotherapy. (theoncologynurse.com)
  • At our world class HSCT hospital in India so far following Auto immune conditions have been treated success fully and continued research and innovation is underway which has benefited hundreds of international patients who came to HSCT Hospital India for HSCT therapy. (hsctindia.com)
Recipients2
  • The study found that rates of latent tuberculosis were 17% in all-HSCT recipients, 24% in auto-HSCT, and 39% in donors. (contagionlive.com)
  • To our knowledge, this is the first study that evaluates the prevalence of LTBI among HSCT recipients in a Latin American country where TB is endemic," the investigators wrote. (contagionlive.com)
Cells13
  • In parallel to my clinical training, I constructed an AML specific CAR and demonstrated its ability to redirect T cell function mediating eradication of AML cells. (stanford.edu)
  • To this end, supported by research demonstrating superior antitumor function of naïve derived effector T cells compared to central memory derived effector T cells, I am investigating whether preferential modification of naïve T cells to express CARs will generate a T cell subpopulation with increased efficacy. (stanford.edu)
  • A CAR is a genetically-engineered receptor made so that immune cells (T cells) can attack cancer cells by recognizing and responding to the CD19/CD22 proteins. (stanford.edu)
  • CAR-T cell therapy involves the removal of a patient's own T cells that are then re-engineered to find and destroy cancer proteins or targets. (curetoday.com)
  • 1 T cells are engineered to express CARs through viral vectors, enabling them to recognize specific target antigens. (bdbiosciences.com)
  • T cell-targeted immunomodulators such as monoclonal antibodies against PD-1 or CTLA4 may be used in combination with CAR-T cells in clinical trials. (bdbiosciences.com)
  • T cells are modified ex vivo by transduction with viral vectors containing CAR or other modifications of interest. (bdbiosciences.com)
  • CAR) T cells are then grown and expanded in defined cell culture conditions and harvested. (bdbiosciences.com)
  • The fourth generation of CAR-T design attempts to deliver cytokines to modulate the tumor microenvironment either by activating host effector T cells or hampering host suppressors and reinforcing memory T cells. (bdbiosciences.com)
  • These experimental cytokine-producing CAR-Ts, called T cells redirected for universal cytokine killing (TRUCKs), can deliver a variety of cytokines, such as IL-12, IL-15, IL-18 or IL-21. (bdbiosciences.com)
  • Haplo-CAR T cells could effectively proliferate in vivo and had a clinically significant antitumor activity without serious side effects. (bmj.com)
  • The technology covered by the newly granted patents enhance the therapeutic potential of DRI cells by enabling their integration with CAR-T technology and CPIs, thereby bolstering the potential effectiveness of the drug therapy against solid tumor cancers. (wearegreenbay.com)
  • Our technology, supported by these newly granted patents opens avenues for expanding the application of these cells in conjunction with CAR-T technologies and checkpoint inhibitors to advance the fight against cancer. (wearegreenbay.com)
Progression2
  • The goal of HSCT is to stop progression, so I'd be happy knowing my MS was not going to get any worse frankly. (mssociety.org.uk)
  • The progression-free survival and overall survival plateau was approximately 45%, which was similar to the outcomes achieved with third-line CAR T-cell therapy. (theoncologynurse.com)
Transplant2
  • Our suggestion is to consider pursuing allo-transplant, even if the patient already achieved only an MRD-negative complete remission from CAR T-cell treatment," she said. (ascopost.com)
  • This raises the question of whether you have to go on to CAR T-cell, or can you continue with high-dose chemotherapy and stem-cell transplant," Dr Zelenetz said. (theoncologynurse.com)
Chimeric antigen1
  • The urgent need for novel treatments inspired me to pursue a research project in adoptive immunotherapy, genetically modifying Tcells to express artificial T cell receptors, termed chimeric antigen receptors (CARs), that target AML specific antigens. (stanford.edu)
Participants1
  • The purpose of this study is to evaluate the effectiveness of vedolizumab when added to background aGvHD prophylaxis regimen compared to placebo and background aGvHD prophylaxis regimen on intestinal aGvHD-free survival by Day +180 in participants who receive allo-HSCT as treatment for a hematologic malignancy or myeloproliferative disorder. (mayo.edu)
Cell therapy7
  • Safe administration of CAR-T cell therapy requires thorough patient selection and patient care in qualified CAR-T cell centers. (deepdyve.com)
  • Some 10 years after the early days of CAR T-cell therapy in the United States, China entered the game and quickly became a research powerhouse. (ascopost.com)
  • Herein, we summarize the clinical data on consolidative allo-HSCT after anti-CD19 CAR T-cell therapy, as well as the potential factors associated with allo-HSCT benefit. (biomedcentral.com)
  • Furthermore, the toxicities of CAR-T cell therapy are manageable. (biomedcentral.com)
  • Several antigens have been used as targets for CAR-T cell therapy against MM, including B cell maturation antigen (BCMA), CD19, CD138, signaling lymphocytic activation molecule 7 (SLAM7), and immunoglobulin light chains. (biomedcentral.com)
  • Furthermore, CAR T-cell therapy is associated with serious adverse events, including cytokine release syndrome (CRS) and neurologic toxicities. (theoncologynurse.com)
  • The thinking now is that if the patient is not in complete response, you can go on to CAR T-cell therapy," Dr Zelenetz noted. (theoncologynurse.com)
Toxicity3
  • There is a concern that labile plasma iron (LPI), the redox-active form of iron, can be involved in the occurrence of toxicity and other complications commonly observed in the early post-HSCT period. (karger.com)
  • First, the pediatric guidelines addressed the clinical toxicity grading and management of the most notable treatment-related side effects: cytokine release syndrome (CRS) and CAR-T cell-related encephalopathy syndrome (CRES). (curetoday.com)
  • Two main advantages of BCMA as an antigen for CAR-T therapy are the potential reduction of on-target/off-tumor toxicity and the lack of antigen-dependent reduction in CAR-T cell expansion [ 16 ]. (biomedcentral.com)
Immune2
  • Immune deficiencies can result in persistent or recurring infections, auto-inflammatory disorders, tumors, and disorders of various organs. (wikipedia.org)
  • Kings College and Hammersmith Hospitals both now run the haematology procedure for auto immune disease. (mssociety.org.uk)
Outcomes1
  • Allo-HSCT might improve upon those outcomes, although the data have been mixed, and the practice remains controversial, she said. (ascopost.com)
Donors1
  • An important barrier to HSCT has been the inability to secure a suitable donors. (medscape.com)
Therapy6
  • As the field of CAR therapy rapidly advances, novel methods to optimize this therapeutic modality are imperative. (stanford.edu)
  • This article summarizes recent developments of CAR-T therapy in MM, focusing on promising targets, new technologies, and new research areas. (biomedcentral.com)
  • Additionally, a comprehensive overview of antigen selection is presented along with preliminary results and future directions of CAR-T therapy development. (biomedcentral.com)
  • This review summarizes the progress of CAR-T therapy in MM. (biomedcentral.com)
  • The choice of target is critical for CAR-T therapy. (biomedcentral.com)
  • CRISPR CAR-T Therapy is Effective - But is it Safe? (patientworthy.com)
Therapeutic1
  • We also discuss the optimal therapeutic window and regimen of consolidative allo-HSCT. (biomedcentral.com)
Hospital3
  • Best and Most Affordable HSCT Hospital. (hsctindia.com)
  • At the world-class HSCT Hospital India, it costs about 30,000 US Dollars, which includes total cost of treatment, stay, medicines and nursing, clinical costs during 30 days stay at a premium private room at the hospital. (hsctindia.com)
  • HSCT Hospital India Wishes Marie from Norway a very happy and healthy life ahead. (hsctindia.com)
Outcome2
  • CAR) design has undergone several levels of enhancements, each step adding to the efficacy and safety of the outcome. (bdbiosciences.com)
  • The outcome of IFD is better in PHO and auto-HCT than in allo-HCT settings. (viamedica.pl)
Disorders2
  • Is HSCT also effective in treating other autoimmune disorders aside from MS? (hsctindia.com)
  • HSCT has also demonstrated promise in treating autoimmune disorders that affect the central nervous system, such as neuromyelitis optica (NMO) and chronic inflammatory demyelinating polyneuropathy (CIDP). (hsctindia.com)
Rapidly1
  • The list of diseases for which HSCT is being used is rapidly increasing, and currently numbers more than 70. (medscape.com)
Cord blood1
  • She has performed more than 80 stem cell transplants, including auto, allo, haplo and cord blood transplants. (hcgoncology.com)
Infusion1
  • Quality control testing is essential to ensure the CAR-T cell product meets established specifications for manufacturing release and patient infusion. (bdbiosciences.com)